Floatz logo

NEOMYCIN

Metastatic Small Intestinal Adenocarcinoma

M.D. Anderson Cancer CentermixturePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

11 Active assets in the Metastatic Small Intestinal Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Ipilimumab
National Cancer Institute (NCI)
Phase 2CCC
Nivolumab
M.D. Anderson Cancer Center
Phase 2CCC
Adenovirus 5/F35-Human Guanylyl Cyclase C-Padre
Thomas Jefferson University
Phase 2CCC
Vancomycin
M.D. Anderson Cancer Center
Phase 2CCC
HUMAN ADENOVIRUS C SEROTYPE 5
Thomas Jefferson University
Phase 2CCC

View all 23 →

Same molecule, other indications

NEOMYCIN is also rated in:

Surgical Site InfectionDormant
BBB
Indicative ·
72 / 100
View asset →
Rectum NeoplasmDormant
BB
Indicative ·
65 / 100
View asset →
Surgery--ComplicationsDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →